Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.medcli.2021.06.014 http://scihub22266oqcxt.onion/10.1016/j.medcli.2021.06.014 34243954!8260823!34243954     free     free     free Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+Clin+(Barc) 2022 ; 158 (12): 608-612 Nephropedia Template TP {{tp|p=34243954|t=2022. Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis |pdf=|usr=}}{{34243954}} gab.com Text Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis JO: Med Clin (Barc) http://www.kidney.de/pget.php?&tw=1&pmid=34243954 #FOAvip BACKGROUND: The effect of immunomodulatory therapy with tocilizumab for coronavirus disease 2019 (COVID-19) in real-life clinical practice remains controversial. METHODS: Single-center retrospective matched cohort analysis including 47 consecutive patients treated with intravenous tocilizumab for severe COVID-19 pneumonia ("TCZ group"), matched by age, comorbidities, time from symptoms onset and baseline SpO(2)/FiO(2) ratio with 47 patients receiving standard of care alone ("SoC group"). RESULTS: There were no significant differences between the TCZ and SoC groups in the rate of clinical improvement (hospital discharge and/or a decrease of >/=2 points on a six-point ordinal scale) by day 7 (51.1% [24/47] versus 48.9% [23/47]; P-value=1.000). No differences were observed at day 14 in terms of clinical improvement (72.3% versus 76.6%; P-value=0.791), all-cause mortality (10.6% versus 12.8%; P-value=1.000), and the composite of invasive mechanical ventilation and/or death (25.5% versus 23.4%; P-value=1.000) either. Patients in the TCZ group had a more rapid normalization of C-reactive protein levels. CONCLUSIONS: No apparent benefit was observed in patients with severe COVID-19 treated with tocilizumab as compared to a matched retrospective cohort. Twit Text FOAVip Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis ????Med Clin (Barc) http://www.kidney.de/pget.php?&tw=1&pmid=34243954 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34243954 #FOAvip English Wikipedia <ref>{{Cite pmid|34243954}}</ref> Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis #MMPMID34243954 Fernandez-Ruiz M; Lopez-Medrano F; Carretero O; Parra P; Ruiz-Merlo T; Aguado JM Med Clin (Barc) 2022[Jun]; 158 (12): 608-612 PMID34243954show ga BACKGROUND: The effect of immunomodulatory therapy with tocilizumab for coronavirus disease 2019 (COVID-19) in real-life clinical practice remains controversial. METHODS: Single-center retrospective matched cohort analysis including 47 consecutive patients treated with intravenous tocilizumab for severe COVID-19 pneumonia ("TCZ group"), matched by age, comorbidities, time from symptoms onset and baseline SpO(2)/FiO(2) ratio with 47 patients receiving standard of care alone ("SoC group"). RESULTS: There were no significant differences between the TCZ and SoC groups in the rate of clinical improvement (hospital discharge and/or a decrease of >/=2 points on a six-point ordinal scale) by day 7 (51.1% [24/47] versus 48.9% [23/47]; P-value=1.000). No differences were observed at day 14 in terms of clinical improvement (72.3% versus 76.6%; P-value=0.791), all-cause mortality (10.6% versus 12.8%; P-value=1.000), and the composite of invasive mechanical ventilation and/or death (25.5% versus 23.4%; P-value=1.000) either. Patients in the TCZ group had a more rapid normalization of C-reactive protein levels. CONCLUSIONS: No apparent benefit was observed in patients with severe COVID-19 treated with tocilizumab as compared to a matched retrospective cohort. |*COVID-19 Drug Treatment[MESH] |*SARS-CoV-2[MESH] |Antibodies, Monoclonal, Humanized[MESH] |Humans[MESH] |Retrospective Studies[MESH]Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective c(epmc).pdf DeepDyve Pubget Overpricing